Early Pathologic Changes and Responses to Treatment in Patients With Later-Onset Pompe Disease - 19/02/12
Communications should be addressed to: Dr. Hwu; Department of Pediatrics; National Taiwan University Hospital; Taipei 10041, Taiwan.Abstract |
The treatment of later-onset Pompe disease with enzyme replacement therapy may not lead to significant improvement in muscle function, probably because of the irreversible muscle destruction caused by glycogen storage. A prospective study was performed to understand early muscle pathology in patients and the response of these pathologic changes to treatment. Five newborns and one child with later-onset Pompe disease but no signs at time of diagnosis were prospectively followed, and treatment was initiated when signs appeared. Six pretreatment biopsies taken at ages 1.5 months to 7 years indicated glycogen storage, lipid storage, stage 4 myocytes, and autophagic debris. Four 6-month posttreatment biopsies revealed glycogen clearance, but stage 4 myocytes and autophagic debris were still evident in three. In conclusion, among patients with later-onset Pompe disease and very mild signs, advanced pathologic changes were evident in a small portion of their myocytes. Because these pathologic changes may not respond to treatment, early treatment is necessary to achieve the best outcomes.
Le texte complet de cet article est disponible en PDF.Plan
Vol 46 - N° 3
P. 168-171 - mars 2012 Retour au numéro
Article précédent
- Developmental Coordination Disorder: A Pilot Diffusion Tensor Imaging Study
- Jill G. Zwicker, Cheryl Missiuna, Susan R. Harris, Lara A. Boyd
- Identification of a Novel Twinkle Mutation in a Family With Infantile Onset Spinocerebellar Ataxia by Whole Exome Sequencing
- Halil Dündar, Rıza Köksal Özgül, Dilek Yalnızoğlu, Sevim Erdem, Kader Karlı Oğuz, Deniz Tuncel, Çağrı Mesut Temuçin, Ali Dursun
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?